Renal AL Amyloid Involvement and NEOD001

Summary

This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a maintained hematologic response to their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[ASCT\]) and have persistent renal dysfunction.

Timeline

Start

2017-07-05

Primary completion

2018-04-23

Completion

2019-02-06

Drugs

Indications